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Introduction
Thiamine-responsive megaloblastic anaemia (TRMA;
OMIM 249270) syndrome is an autosomal recessive disorder
characterized by diabetes mellitus, megaloblastic anaemia,
and sensorineural deafness. The syndrome was first
described by Porter et al (1). Thirty years later, SLC19A2, the
gene encoding a high-affinity thiamine transporter protein
(THTR-1), was identified by three independent groups (2,3,4).
To date, 29 distinct mutations in this gene have been
described in a total of 70 reported patients (5). Progressive
hearing loss is one of the cardinal findings of the syndrome
and is known to be irreversible. However, most of the TRMA
cases reported to date have been diagnosed after infancy and
the hearing loss was already present in many at the time of
diagnosis. Here, we report a four-month-old female infant
who presented with megaloblastic anaemia and 
hyperglycemia and was diagnosed as a case of TRMA 
syndrome in the absence of hearing loss. Although treatment
with thiamine was started at an early age, development of
deafness at 20 months of age could not be prevented. 
Case Report 
A four-month-old girl presented to our clinic with vomiting
and pallor that was noticed about one month ago. She 
was born to nonconsanguineous parents at term after an
uneventful pregnancy with a birth weight of 3800 g. She was
the fourth child of the parents. The infant was breast-fed from
birth onwards. Family history was negative for diabetes,
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weight was 5800 g (25th  percentile), height was 60 cm 
(25th  percentile), and head circumference was 39.5 cm 
(25th  percentile). Physical examination  findings were 
normal, except for pallor. Audiological and ophthalmological
examinations were also normal. Laboratory investigations
showed anaemia, thrombocytopenia and hyperglycemia.
White blood cell count was 7 000/μL with 70% lymphocytes.
Other haematological findings: Hb 6.6 g/dL, Hct 20.6%, MCV
96.3 fL, platelets 50 000/μL. Reticulocyte count was 1%.
Blood smear revealed anisocytosis, poikilocytosis, and
macrocytic erythrocytes along with some polynucleated
cells. Biochemical findings were: glucose  280 mg/dL, ALT
25 U/L, AST 35 U/L, BUN 10 mg/dL, creatinine 0.5 mg/dL, Ca
9.0 mg/dL, P 4 mg/dL, Na 132 mmol/L, and K 5 mmol/L.
Blood gas analysis was normal. On follow-up, blood glucose
levels were found to show small changes, around 
200 mg/dL. HbA1c level was 5% (N: 3.5-6.5), while insulin
and C-peptide levels were 0.9 mIU/mL (N: 4-16) and 0.05
ng/mL (N: 0.20-0.52), respectively. Folic acid and vitamin B12
levels were normal being 7.25 ng/mL (N: 3-17) and 626
pg/mL (N: 193-985), respectively. Vitamin B1 level was 13.5
μg/L (N: 28-85).
Examination of the bone marrow aspirate specimen
demonstrated increased megaloblastic erythropoiesis and
megakaryopoiesis.
The otoacoustic emission test, which was performed at
neonatal screening for deafness, was normal. The repeated
test as auditory evoked brainstem responses (ABRs) at the
onset of the disease was also normal. 
The findings of severe macrocytic anaemia, 
thrombocytopenia and hyperglycemia led us to consider a
presumptive diagnosis of TRMA, and oral thiamine therapy in
a dose of 100 mg/day was started. Hyperglycemia resolved
three days later. Haemoglobin levels increased gradually and
reached 10.6 g/dL by day 16 of the treatment. Platelet count
also increased and normalized within 5 days. The diagnosis
of TRMA was confirmed by molecular genetic testing, which
showed a homozygous mutation in SLC19A2 gene with 
two-base-pair deletion and three-base insertion,
566_567delGCinsTCT, that results in Insdel 189fs/ter239. .
At the follow-up visit at age 20 months, the patient, 
who had been receiving 100 mg/day of oral thiamine 
supplementation, had neither anaemia nor hyperglycemia.
Her somatic and motor development was appropriate for
age, but she could utter only a few words. The parents were
not aware of any hearing loss. ABR test was performed and
bilateral moderate sensorineural hearing loss was detected.
The patient was referred to an otolaryngologist for evaluation
for hearing device implantation.
Discussion 
Thiamine pyrophosphate, also known as vitamin B1, is a
coenzyme required for several key steps in intermediary
metabolism  (6). The deficiency of SLC19A2 gene product
THTR-1 results in defective transport of thiamine into cells (7).
TRMA syndrome is an autosomal recessive disorder
characterized by diabetes mellitus, megaloblastic anaemia,
and sensorineural deafness. In addition to these cardinal
components, other findings including thrombocytopenia,
pancytopenia, optic atrophy, retinal degeneration, situs 
inversus, cardiomyopathy, arrhythmias, congenital heart
defects, and stroke have been reported in association with
TRMA syndrome (8,9,10,11). In our patient, megaloblastic
anaemia was accompanied by thrombocytopenia and both
responded well to the treatment with thiamine within two
weeks. Cardiological and ophthalmological examinations
revealed no pathology. The gene SCL19A2 causing TRMA
syndrome has been mapped to chromosome 1q23.2-23.3
(12). To date, 29 distinct clinical mutations have been 
identified in SLC19A2 comprising point mutations, as well as
premature truncations resulting from missense, nonsense,
frameshift, and very recently, from compound heterozygous
mutations  (5). We found a homozygous mutation with 
two-base-pair deletion and three-base insertion,
566_567delGCinsTCT, which results in Insdel 189fs/ter239.
It is predicted to be null. The mutation found in this case has
been recently described as a novel mutation in another
Turkish family unrelated to our patient and living in a different
geographical area. That patient was diagnosed at age 
two years and, contrary to our case, had already developed
deafness (13). We suggest that a not-yet-determined founder
effect for this allele may be responsible for the difference in
the timing of development of deafness.  
Diabetes mellitus in TRMA syndrome is due to a 
nonimmune mechanism and is most likely secondary 
to impairment of islet cell function caused by intracellular 
thiamine deficiency. In this syndrome, diabetes usually 
develops in early childhood and the response to thiamine
treatment is variable (14). At puberty, probably due to
increased β-cell apoptosis, insulin may be required in addition
to thiamine treatment to control diabetes (15). Although 
diabetic ketoacidosis is rare in TRMA patients, it can occur
even in prepubertal ages if thiamine supplementation is
insufficient (16). Although the initial levels of serum insulin
and C-peptide were low in our case, hyperglycemia resolved
in three days by thiamine treatment only. Insulin was 
not required and hyperglycemia did not recur during the 
follow-up period of about two years.
Sensorineural deafness is one of the cardinal findings of
TRMA syndrome. A high-affinity transporter protein 
is expressed in the inner hair cells within the cochlea (17). 
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created with targeted disruption of SCL19A2 gene (18). In
their study describing auditory phenotype of this mouse line,
Liberman et al (19) demonstrated selective loss of inner hair
cells after 1-2 weeks on low-thiamine diet, which is an
uncommon pattern for sensorineural hearing loss. Obviously,
the degree of inner hair cell loss depended on the duration
and magnitude of thiamine deprivation. Interestingly, they
showed normal cochlear function in these mutants when
maintained on a high-thiamine diet. In another animal study,
Oishi et al (20) showed that ABR thresholds were markedly
high in SCL19A2 (-/-) mice on thiamine-free diet, while normal
in thiamine-fed SCL19A2 (-/-) mice and in the wild types.
These findings may support the hypothesis that early 
treatment with thiamine can prevent hearing loss in patients
with SLC19A2 gene mutations. Initially, we speculated that
the hearing loss in the present case might have been 
prevented by early treatment. Unfortunately, despite the 
regular thiamine supplementation (100 mg/day), deafness
developed at age 20 months. 
Since patients usually present to a clinic at a late stage, it
is difficult to define the actual time of symptom onset. Mild
hearing loss may not be noticed by parents in the early
months of life, therefore, all infants should be evaluated by
hearing tests. In our patient, the initial otoacoustic emission
test, which was performed at neonatal screening for 
deafness, was normal. The ABRs measured at age four
months were also normal. However, the repeated test (ABR)
performed at 20 months of age, when the patient was under
regular thiamine treatment, showed bilateral moderate 
sensorineural hearing loss. Long-term follow-up findings of
three patients with TRMA have been reported recently (21).
Two of these patients were already deaf on presentation, but
the youngest one was symptom-free till hyperglycemia
developed at age 3. Although thiamine treatment was 
started at that age, hearing loss occurred at age 5. 
In prior reports, all patients with mutations in SLC19A2
were homozygous. In a very recent paper, Bergmann et al (5)
reported for the first time four compound heterozygous
mutations. Interestingly, two of these patients possessed
less severe hearing phenotype-one had normal hearing even
at age 15 and the other one had only minimal hearing loss at
age 30. It was not clarified whether these milder 
phenotypes were attributable to compound heterozygosity.
Our patient had a known homozygous mutation in SLC19A2.
To our knowledge, there is no case report published in the 
literature with such mild hearing phenotype among TRMA
patients with homozygous mutations.
Recently, a one-month-old female patient with TRMA
syndrome who presented without diabetes or hearing loss
and did not develop deafness until 32 months of age was
reported from Turkey (22). The mutation identified in that
case, 242insA, was different from the one in our patient. The
authors suggest that deafness was prevented by early 
diagnosis and treatment, but we believe further follow-up is
needed to confirm this conclusion. 
The dose of thiamine necessary to treat or prevent the
symptoms of TRMA syndrome and the timing of therapy are
not yet clarified. The time of onset of histopathological
changes caused by intracellular thiamine deprivation is also
not known. Theoretically, these alterations may begin even in
intrauterine life. However, it seems logical to assume that
the earlier the treatment starts, the better the response will
be in these patients. 
In conclusion, TRMA syndrome should be kept in mind in
the differential diagnosis of hyperglycemia coexistent with
megaloblastic anaemia. Deafness, a cardinal component of
the syndrome, may not be present at the onset of the 
disease in infancy. Early institution of   appropriate thiamine
supplementation does not appear to prevent hearing loss in
these patients. However, it still needs to be proven whether
early treatment with higher doses of thiamine can prevent
deafness. As the number of cases diagnosed with TRMA
syndrome at a very early age increases, the role of thiamine
in prevention of deafness will be further elucidated by future
studies.
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